In this study, we observed a substantial difference in the expression of HER-2 marker between hereditary and non-hereditary breast cancer patients (P < 0.05); Based on the results of the further analysis, we speculated that patients with hereditary breast cancer, especially those with CHBC, may respond better to HER-2-targeted drugs. This evidence concerns the gene ERBB2 and breast carcinoma.